BioSpace News Archive

Kraig Biocraft Laboratories, Inc., comments on an exciting advancement in spider silk engineering from the Rensselaer Polytechnic Institute.

Apollomics Inc. announced financial results for the full year ended December 31, 2023, and highlighted progress of its pipeline.

Xilio Therapeutics, Inc. announced that it has entered into a securities purchase agreement with certain existing accredited investors, including Bain Capital Life Sciences and Rock Springs Capital.

Agile Therapeutics, Inc. (Pink: AGRX), a women’s healthcare company, today reported financial results for the three and twelve months ended December 31, 2023 and provided a corporate update.

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 10 pre-split shares.

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company today announced positive topline results from a Phase 2 clinical study of LPCN 1148. LPCN 1148 is an oral candidate under development for the clinical management of cirrhosis, specifically prevention of OHE recurrence and treatment of sarcopenia.

ProJenX announced that the United States Food and Drug Administration has removed a partial clinical hold on Study PRO-101, a hybrid Phase 1 clinical trial evaluating prosetin—a first-in-class MAP4 kinase inhibitor—in healthy volunteers and participants with ALS.

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical company, today announces its anticipated financial results for the quarter and year ended December 31, 2023 and provides the following summary of its expected annual report to be filed later today.

Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the Company will present data on EDG-7500 at the American College of Cardiology’s Annual Scientific Session (ACC.24).

TransCode Therapeutics, Inc. announced that Daniel Vlock, M.D., has been appointed as the company’s Chief Medical Officer.